Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity
Mol Cancer
.
2021 Jan 27;20(1):21.
doi: 10.1186/s12943-021-01319-5.
Authors
Yann Cheli
1
,
Meri K Tulic
2
,
Najla El Hachem
3
,
Nicolas Nottet
4
,
Arnaud Jacquel
5
,
Maeva Gesson
6
,
Thomas Strub
4
,
Karine Bille
4
,
Alexandra Picard-Gauci
7
,
Henri Montaudié
7
,
Guillaume E Beranger
4
2
,
Thierry Passeron
2
7
,
Pierre Close
3
,
Corine Bertolotto
#
4
,
Robert Ballotti
#
4
Affiliations
1
Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France.
[email protected]
.
2
Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000, Nice, France.
3
Laboratory of Cancer Signaling, University of Liège, Liège, Belgium.
4
Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France.
5
Université Nice Côte d'Azur, INSERM, U1065, Team2 Cell death, differentiation and cancer, 06000, Nice, France.
6
Université Nice Côte d'Azur, INSERM, U1065, Imaging platform, 06000, Nice, France.
7
CHU NICE, Département de Dermatologie, 06000, Nice, France.
#
Contributed equally.
PMID:
33504341
PMCID:
PMC7839296
DOI:
10.1186/s12943-021-01319-5
No abstract available
Publication types
Published Erratum